biologic

Zaltrap

Ziv-Aflibercept

Loss of exclusivityAugust 2024projected — 12-year biologic exclusivity estimate
CompanySanofi-Aventis U.S. LLC

Drug detail

Brand nameZaltrap
Active ingredientZiv-Aflibercept
Strength200MG/8ML (25MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalAugust 2012
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Zaltrap patent cliff — loss of exclusivity August 2024 | CliffBio